Afuco™ Anti-Human VEGFC ADCC Recombinant Antibody (VGX100), ADCC Enhanced (CAT#: AFC-635CL)
Anti-VEGFC ADCC Enhanced Antibody (VGX100) is an ADCC enhanced antibody produced by our Afuco™ platform. VGX-100 is a human antibody that acts against the human vascular endothelial growth factor (VEGF)-C protein. Treatment for cancers, particularly glioblastoma and metastatic colorectal cancers, are the first target indications for VGX-100. Additionally, VGX-100 is developing for a number of other cancer indications, and as an agent to treat front-of the-eye diseases.
Specific Inquiry
RNA Expression
Figure 1 RNA cell line category: Cell line enhanced.
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000150630-VEGFC
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000150630-VEGFC
Specifications
- Host Species
- Human
- Derivation
- Human
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Applications
- Neut, FuncS
- Related Disease
- Glioma; Prostate Cancer; Solid Tumors
Product Property
- Purity
- >97%, by SDS-PAGE under reducing conditions
- Storage
- Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.
Applications
- Application Notes
- VEGF-C Neutralization with Blocking Antibody
VEGF-C was blocked using neutralizing monoclonal anti-VEGF-C (VGX-100). VGX-100 was commercially supplied, based on a signed material transfer agreement; and according to the manufacturer, VGX-100 binds to and precipitates all forms of VEGF-C including full-length, partially processed, and mature forms in both the human and mouse. To block VEGF-C, 20 mg/kg (in total 0.1 mL volume) of VGX-100 was injected from the day before surgery, through the intraperitoneal route and on alternate days subsequently up to 2 weeks. Control mice received 0.1 mL of normal saline intraperitoneally.
Target
- Alternative Names
- VEGFC; vascular endothelial growth factor C; VRP; Flt4-L; LMPH1D; FLT4 ligand DHM; vascular endothelial growth factor-related protein
- Gene ID
- 7424
- UniProt ID
- P49767
Related Resources
TNF Signaling Pathway
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "VEGFC"
Select a product category from the dropdown menu below to view related products.
Please select product type
IgG Antibody Products
Human Antibody Products
Humanized Antibody Products
Mouse Antibody Products
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-1722z | Mouse Anti-VEGFC Recombinant Antibody (clone 10F5) | WB, ICC, IF, IHC | Mouse IgG2a |
| MOB-2183MZ | Recombinant Mouse Anti-Human VEGFC Antibody (clone 0/F8) | IHC-Fr, WB | Mouse antibody |
| MRO-2271-CN | Rabbit Anti-VEGFC Polyclonal Antibody (MRO-2271-CN) | WB, IF, IHC, FC | Rabbit IgG |
| VS3-QX1233 | Mouse Anti-VEGFC Recombinant Antibody (clone 2E2-F8-C6) | WB | |
| VS-0224-XY139 | Mouse Anti-VEGFC Recombinant Antibody (VS-0224-XY139) | ELISA, WB, FC, IF, IP, IHC | Mouse IgG2a, kappa |
Customer Reviews and Q&As
Customer Review
Q&As
Robust immune response
I've used VGX100 in my oncology research, and the enhanced ADCC activity has significantly improved our results compared to traditional anti-VEGFC antibodies. The immune response is much more robust, which is critical for our therapeutic development.
Consistent potency and stability
We followed the recommended storage guidelines for VGX100 and observed consistent potency and stability over a six-month period. Proper storage is indeed crucial for maintaining its efficacy.
Better results with enhanced Fc region
The enhanced Fc region in VGX100 has made a noticeable difference in our efficacy studies. The level of immune cell engagement and subsequent tumor cell lysis was significantly higher compared to standard antibodies.
Popular products with customers
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, WB
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
-1-1.png)
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC
Application: WB, ELISA, FC, IHC, IP
Application: ELISA, IHC, FC, WB, IF, IA
Application: SPR, Inhib, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
